Avid Bioservices Inc (CDMO)

[JJ1223]

$8M + contingencies is a pretty good price for a placebo-like drug. This may be the shrewdest business transaction CDMO/PPHM has ever made.

They acquired the patent rights to target PS for $8M and will continue development with NCCN. Unless they have determined that patents will not hold up in court, this is a bad deal for shareholders. There are many BP’s
now that are investigating and targeting phosphatidylserine with their own drugs.